A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Guadecitabine (Primary)
- Indications Chronic myeloid leukaemia; Myeloid leukaemia; Myeloproliferative disorders
- Focus Therapeutic Use
- 06 Nov 2019 Interim analysis results (n=20) released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 12 Mar 2019 Planned End Date changed from 1 Dec 2019 to 15 Jun 2020.
- 12 Mar 2019 Planned primary completion date changed from 1 Jun 2019 to 15 Dec 2019.